Ojemba is an oral, brain-penetrant, highly-selective type II RAF kinas inhibitor designed to target a key enzyme in the MAPK signaling pathway. Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions.
Ojemba is an oral, brain-penetrant, highly-selective type II RAF kinas inhibitor designed to target a key enzyme in the MAPK signaling pathway. Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions.
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most.